AcuCort AB has signed a commercial agreement with Glenmark Pharmaceuticals Ltd. for the marketing and distribution of Zeqmelit in six European countries, including Germany. The financial terms were not disclosed. Glenmark will handle commercialisation in Germany, the Netherlands, the Czech Republic, Austria, Slovakia, and Ukraine, with a combined population of over 160 million. Marketing authorisation applications are expected to be filed in the second half of 2026. Glenmark Pharmaceuticals stock is up 1.96% on the National Stock Exchange, while AcuCort AB closed trading 0.16% higher on the Stockholm Stock Exchange.

Read more at Nasdaq.: AcuCort Signs Glenmark Deal To Market Zeqmelit In Six European Countries